Global and China Monoclonal Antibody Industry Report, 2013 - 2017
Published Date » 2013-12-23
No. Of Pages » 118
Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.
Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).
The global monoclonal antibody industry is still dominated by European and American companies, especially, important monoclonal antibody products are mainly produced by Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the above four companies. The global sales (including the sales of third parties) of these six monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.
Propelled by the optimistic market prospect, advancement of monoclonal antibody technologies and the upcoming patent expiration of several key monoclonal antibody agents, the research and industrialization of monoclonal antibody agents has become a global investment highlight, wherein the future market competition will be evident.
In September 2013, the Infliximab generic drug - Inflectra developed by South Korea Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon together was available in the market under the permit of Drug Controller General Of India. Mylan will sell the product tagged with the brand name Hertraz in India in early 2014.
In addition, India Biocon's first anti-CD6 Alzumab (Itolizumab) for the treatment of chronic plaque psoriasis was approved to be sold in India in August 2013.
In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012.
However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year).
Meanwhile, the R & D of monoclonal antibody has also made progress. The Adalimumab generic drug developed by Huahai Pharmaceutical and American Oncobiologics jointly was ratified by the EU EMA and the U.S. FDA in December 2013 and the clinical trial Phase I was implemented. The Trastuzumab generic drug of Genor Biopharma was granted with Australian Clinical Preliminary Summary Report Phase I in August 2012 and SFDA's clinical trial approval in July 2013.
Table of Content
1 Overview of Monoclonal Antibody Industry
1.3 Technological Development
2 Overview of Global Monoclonal Antibody Industry
2.1 Status Quo
2.2 Market Size
2.3 Competition Pattern
2.4 Development Prospect and Prediction
2.4.1 Market Size
2.4.2 Competition Pattern
2.4.3 R & D Trend
3 Chinese Monoclonal Antibody Market
3.1 Status Quo
3.2 Market Size
3.3 Market Segments
3.3.6 Recombinant Human Tumor Necrosis Factor Receptor Type II - Antibody Fusion Protein
3.4 Competition Pattern
3.5 Development Prospect
4 Key Foreign Monoclonal Antibody Agent Enterprises
4.1 Roche Pharmaceuticals
4.1.3 Revenue Structure
4.1.4 R & D and Investment
4.1.5 Monoclonal Antibody Business (Genentech)
4.1.6 Business in China
4.2 Johnson & Johnson
4.2.3 Revenue Structure
4.2.4 R & D and Investment
4.2.5 Monoclonal Antibody Business
4.2.6 Business in China
4.3.3 Revenue Structure
4.3.4 R & D and Investment
4.3.5 Monoclonal Antibody Business
4.3.6 Business in China
4.4.3 Revenue Structure
4.4.4 R & D and Investment
4.4.5 Monoclonal Antibody Business
4.4.6 Business in China
4.5.2 Revenue Structure
4.5.3 R & D and Investment
4.5.4 Monoclonal Antibody Business
4.5.5 Business in China
4.6.3 Revenue Structure
4.6.4 R & D and Investment
4.6.5 Monoclonal Antibody Business
4.6.6 Business in China
5 Key Chinese Monoclonal Antibody Agent Enterprises
5.1 Shanghai Lansheng States Kin Pharmaceutical Co., Ltd.
5.1.2 Shanghai CP Guojian Pharmaceutical Co., Ltd.
5.1.3 Shanghai Zhangjiang Biotech Co., Ltd.
5.1.4 Shanghai CP GuoJian Biotech Academy
5.1.5 Shanghai Guosheng Pharmaceutical Co., Ltd.
5.2 Beijing Biotech Pharmaceutical Co., Ltd.
5.2.2 Competitive Edges
5.2.3 Development Prospect
5.3 Chengdu Huasun Group Co., Ltd.
5.3.2 Chengdu Huasun Biotech Co., Ltd.
5.4 Shanghai Medipharm Biotech Co., Ltd.
5.4.2 Monoclonal Antibody Business
5.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.5.2 Monoclonal Antibody Business
5.6 Yunnan Walvax Biotechnology Co., Ltd.
5.6.2 Monoclonal Antibody Business
5.7 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.7.2 Monoclonal Antibody Business
5.8 Beijing SL Pharmaceutical Co., Ltd.
5.8.2 Monoclonal Antibody Business
5.9 Shenzhen Main Luck Pharmaceuticals Inc.
5.9.2 Monoclonal Antibody Business
5.10 Huahai Pharmaceutical Co., Ltd.
5.10.2 Monoclonal Antibody Business
6 Summary and Forecast
6.1 Comparison between Domestic and Foreign Companies
6.2 Market Forecast
List of Tables
List of Figures
Microwave Ovens Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
The global microwave oven market is projected to grow to $72.5 million by the year 2015 mainly driven by the replacement demand, niche product development and re-establishment of old product line in developed markets of America and Europe. Increasing income levels and growing living standards are influencing the growth of this market across the developing markets of Asia and Eastern Europe. Due to the increasing need of luxury gadgets, microwave ovens are becoming an essential part of modern and well furnished kitchen. Number of technological developments and improvements in design...
Medication Management Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
The purpose of medication management, a nursing intervention, is to optimize the use of medications administered to patients and enable their safe outcome. Presently, medication management service providers are keen on providing professional-assisted medication management regime for patients and assure their safety at all stages of their recovery. Medication management systems operate at hospitals, private healthcare centers and at personal levels. The regime at personal level includes regular visits of assigned healthcare professionals, organizing weekly medications, ensuring...
Global Plasticizers Market - Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2011 - 2018
By - Transparency Market Research
Plasticizers are additives that increase the plasticity and fluidity of a material. They are known for their effectiveness in producing flexible plastics for applications in many industries such as automotives, medical and consumer goods. Plasticizers are one of the best selling chemicals worldwide. The global plasticizers market has shown remarkable growth in recent years. The global plasticizers market has registered revenue of USD 26 billion in 2009 and is expected to reach USD 36.7 billion by 2015. The global annual demand for the plasticizers market is projected to...
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Select License type:
- Global and China Reading Chair Industry 2014 Market Research Report
- Global and China Refer Table Industry 2014 Market Research Report
- Global and China Positive PS plate developer powder Industry 2014 Market Research Report
- Global and China Diethylene glycol diacrylate Industry 2014 Market Research Report
- Global and China Printed sets of drugs Industry 2014 Market Research Report
- The Mobile Advertising (mAdvertising) Market: 2014 - 2020 - Opportunities, Challenges, Strategies & Forecasts
- The Mobile Security (mSecurity) Bible: 2014 - 2020 - Device Security, Infrastructure Security & Security Services
- The NFV, SDN & Wireless Network Infrastructure Market: 2014 - 2020
- Global and China Ozone Generator Industry 2014 Market Research Report
- Global and China Diazo -2,1,4 - salt Industry 2014 Market Research Report
Microsoft to Complete Nokia Purchase by April 25
Apr 23, 2014
The Microsoft-Nokia deal that made headlines when it was announced is finally on its way to being completed. This proves that even the most complex deals do culminate with time. This week, Microsoft announced that it would complete the purchase of a major part of Nokia’s hardware assets by Friday. The much discussed deal-though on the brink of completion-has witnessed some adjustments...
Top End Stereo Systems Maker Harman Targets Chinese Auto Market
Apr 22, 2014
Harman, the U.S.-based audio company that is best known as the provider of automobile stereos for top-end car models such as Mercedes-Benz, BMW and Ferrari, has said that it has signed agreements with two leading Chinese automakers—Chang’An and Geely. The company, that is associated with premium infotainment systems for leading auto makers, said that these new contracts...
Scientists Identify Cure for Dengue
Apr 18, 2014
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year. Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai. The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis. Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods. This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...